申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20170129892A1
公开(公告)日:2017-05-11
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.